



Association of Breast Surgery Conference & AGM

A large, modern building with a prominent arched glass and steel facade. A clock is visible on the central part of the arch. In the foreground, there are wide stone steps with metal railings leading up to the building. The sky is clear and blue.

CONFERENCE PROGRAMME

21st & 22nd May 2013, Manchester Central

Over 300,000 assays reported for 65+ countries

The **Oncotype DX**[®] Breast Cancer Assay

Revealing the underlying tumour
biology helping to decide:

Chemo? No Chemo?

Personalised information to support therapy
decision-making for newly diagnosed patients with
ER-positive, HER2-negative invasive breast cancer

Visit us at www.oncotypedx.co.uk

For information on how to order the **Oncotype DX** Breast Cancer Assay, please contact the UK team
on 020 3440 5150, or International Customer Service at international@genomichealth.com

This piece is intended to educate physicians on the clinical utility of the Oncotype DX Breast Cancer Assay, and should not be provided to patients.
Genomic Health and Oncotype DX are trademarks of Genomic Health, Inc. © 2012 Genomic Health, Inc. All rights reserved. GHI10031_0312_EN_UK

Welcome from the President



Welcome to Manchester for what promises to be a very busy and informative two days. A brief glance at the programme will confirm the breadth and depth of the topics covered by a rich selection of opinion leaders. I am indebted to all of you for your continued interest and support, and to our many sponsors for their ongoing financial commitment - please do take some time out to visit their stands. With your help, the Association has blossomed into a major organisation with the confidence and the experience to host this world class meeting.

This year we're focusing on a wide range of current and controversial topics. Many of these have been prioritised by our members - management of the axilla both before and after systemic treatment, lessons from the recent screening review, new data on partial breast irradiation and the impact of surgical and other interventions in the high risk patient. Dedicated symposia and keynotes by world experts promise to stimulate discussion and bring us right up to date. Mark Sibbering has once again produced a programme which has very broad appeal, with topics as diverse as survivorship, enhanced recovery, oncoplastics, litigation, and new approaches to endocrine therapy.

Finally, do sample and enjoy the quality and diversity of our submitted paper and poster sessions. We've been thrilled to receive a record number of high quality abstracts, many from our younger members. It's a really welcome trend which reflects our new identity and status as an expanding, healthy and above all youthful organisation.

Have a great meeting!

A handwritten signature in black ink, which appears to read 'Dick Rainsbury'. The signature is written in a cursive style with a long, sweeping underline.

Dick Rainsbury
President of the ABS



Accelerating the time from images to answers.

Trident™ Specimen Radiography System

The all-inclusive Trident dedicated specimen radiography system provides rapid verification, reduces procedure time, streamlines workflow, and helps to improve the standard of care for your patients.

Across departments - Radiology, Surgery, and Pathology - the Trident system delivers:

- **Clarity.** Achieve high-resolution image quality from the same exclusive Selenium detector technology utilised in our best-in-class Selenia® and Selenia® Dimensions® mammography systems.
- **Insight.** Intuitive software with enhanced visualisation tools help you gain rapid confirmation of the presence of targeted lesions or micro-calcifications in the breast and reduces procedure steps.
- **Confidence.** Minimise the potential for surgical re-excision and the time needed for additional core biopsy specimens.



Hologic UK Ltd
 Unit 2, Link 10
 Napier Way
 Crawley, Sussex RH10 9RA
 United Kingdom
 Tel: +44 (0)1293 522080
 www.hologic.com

Hologic, Dimensions, Selenia, Trident are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative.


HOLOGIC®



Strattice™
 RECONSTRUCTIVE TISSUE MATRIX

Strattice™ Reconstructive Tissue Matrix (TM) An *Intact* Matrix

The **ONLY** Acellular Dermal Matrix proven to reduce the cost consequence of Breast reconstruction surgery versus alternative standard techniques¹



Strattice™ Tissue Matrix Contour shapes **NEW** for 2013
Designed to enhance **ease of use**

Please contact your local LifeCell™ Business Manager for more details

www.lifecell.com

1. Johnson RK et al. Cost minimisation analysis of using acellular dermal matrix (Strattice™ Tissue Matrix) for breast reconstruction compared with standard techniques. *Eur J Surg Oncol* (2012) <http://dx.doi.org/10.1016/j.ejso.2012.12.002>

© 2013 LifeCell Corporation. All rights reserved.
LifeCell™ and Strattice™ are trademarks of LifeCell Corporation MLC 3490-EU/3077/2-2013

LifeCell EMEA Ltd
 Langford Business Park,
 Langford Locks
 Kidlington OX5 1GF
 United Kingdom
 Tel: 00800 200 80 400
 E-mail: Contact@LifeCell.com

 **LifeCell™**



ASSOCIATION OF
BREAST SURGERY

Conference & AGM Programme

21st & 22nd May 2013, Manchester Central

Tuesday 21st May 2013 - At a glance

	Exchange Auditorium	Exchange 8 - 10	Exchange 11
09:00 to 10:30	Session 1 BJS Prize Papers	Session 2 Survivorship	Session 3 Submitted Papers
10:30 to 11:00	Tea & Coffee Break (Exchange Hall)		
11:00 to 12:30	Session 4 Breast Cancer Screening	Session 5 Mammary Fold Session	Session 6 Personal finance planning
12:30 to 14:00	Lunch (Exchange Hall)		
12:30 to 13:15	ABS AGM (open to ABS Members only)		
13:15 to 13:45		ABS Affiliate and Nurse Unit Members' Business Meeting	
14:00 to 15:00	Session 7 The axilla		
15:00 to 16:00	Session 8 Partial Breast Radiotherapy	Session 9 Breast Care Nurse's role in Breast Cancer Screening	Session 10 Submitted papers
16:00 to 16:30	Tea & Coffee Break (Exchange Hall)		
16:30 to 18:00	Session 11 Familial Breast Cancer	Session 12 Breast Cancer Research & Trials	Session 13 Everyday surgical issues
18:00 to 18:30			Mammary Fold AGM
18:00 to 19:00	Poster Viewing and Drinks Reception (Exchange Hall)		

Webcasts of most of the presentations from the conference will be available on the ABS website shortly.

See the website for further details:

www.associationofbreastsurgery.org.uk

Tuesday 21st May 2013

09:00 to 10:30	Exchange Auditorium
Session 1	BJS Prize Papers
Chairs:	Mr Dick Rainsbury & Mr Kieran Horgan
09:05 to 09:15	1. The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular carcinoma and invasive ductal carcinoma <i>Mr Ashley Topps, University Hospital of South Manchester NHS Foundation Trust</i>
09:15 to 09:25	2. Epidermal Growth Factor Receptor (EGFR) expression confers poor prognosis in HER2 positive breast cancers <i>Ms Amy Robinson, Queen Elizabeth Hospital, Gateshead</i>
09:25 to 09:35	3. Overall size of metastases in the tumour positive sentinel nodes; an important predictor of residual axillary disease <i>Mr Rana Nadeem, Lancashire Teaching Hospital, Preston</i>
09:35 to 09:45	4. The clinical incidence of cytokeratin-19 negative breast cancers <i>Dr Dionysios-Dennis Remoundos, Wycombe Hospital, High Wycombe</i>
09:45 to 09:55	5. Pre-operative MRI scanning changes surgical strategy in core-biopsy proven lobular breast cancer <i>Mr Simon Pilgrim, Addenbrooke's Hospital, Cambridge</i>
09:55 to 10:05	6. The prognostic significance of tumour-stromal ratio in oestrogen receptor-positive breast cancer <i>Dr Candice Downey, University of Leeds</i>
10:05 to 10:15	7. Changing trends in consultant practice and breast training in the United Kingdom <i>Mr Loai Maraqa, Nottingham City Hospital</i>
10:15 to 10:25	8. Molecular phenotypes of DCIS predict invasive and DCIS recurrence <i>Ms Kathryn Williams, University Hospital of South Manchester</i>

09:00 to 10:30	Exchange 8 - 10
Session 2	Survivorship
Chair:	Dr Carmel Sheppard
09:00 to 09:20	Managing chronic pain <i>Ms Rachel Rawson, Breast Cancer Care</i>
09:20 to 09:40	Intimacy after breast cancer <i>Miss Victoria Harmer, Imperial College Healthcare NHS Trust</i>
09:40 to 10:00	Cognitive behavioural therapy for managing hot flushes <i>Prof Myra Hunter, Kings College London</i>
10:00 to 10:20	Treatment of menopausal endocrine therapy related side effects <i>Prof Michael Dixon, Western General Hospital, Edinburgh</i>
10:20 to 10:30	Discussion

Tuesday 21st May 2013

09:00 to 10:30	Exchange 11
Session 3	Submitted Papers
Chairs:	Miss Fiona MacNeill & Mr Simon Cawthorn
09:00 to 09:08	9. 232 sheets of acellular dermal matrix, or how we spent £500,000 on pig skin <i>Mr Matthew Barber, Western General Hospital, Edinburgh</i>
09:08 to 09:16	10. Patient reported outcomes in intermediate breast reconstruction: Acellular Dermal Matrix is more comparable to autologous rather than implant based reconstruction <i>Mrs Rachel Brindle, University Hospital of South Manchester</i>
09:16 to 09:24	11. Short-term oncological safety of oncoplastic breast conservation surgery - the Glasgow experience <i>Mr Laszlo Romics Jr, Victoria Infirmary, Glasgow</i>
09:24 to 09:32	12. Local recurrence after skin sparing mastectomy and Latissimus Dorsi Breast Reconstruction; single centre experience with > 10 years follow up <i>Mr Jeffrey Lim, The Great Western Hospital, Swindon</i>
09:32 to 09:40	13. Partial breast reconstruction with pedicled perforator flaps for patients with breast cancer: our initial experience <i>Ms Ruth James, Oxford University Hospitals Trust</i>
09:40 to 09:48	14. A retrospective analysis of patients with margin positive wide local excision for DCIS to evaluate predictors that aid the decision between re-excision of margins or completion mastectomy <i>Ms Lucy Mansfield, Queen Alexandra Hospital, Portsmouth</i>
09:48 to 09:56	15. The impact of a change in margin width policy on rates of re-operation for breast conserving surgery <i>Ms Caroline Richardson, Cambridge University Hospitals NHS Foundation Trust</i>
09:56 to 10:04	16. Mode of detection of recurrence in operable invasive breast cancer <i>Mr Thomas Nedumpara, North Cumbria University Hospital NHS Trust, Carlisle</i>
10:04 to 10:12	17. Contralateral breast cancer in high-risk patients: Identification of risk factors to guide recommendations for contralateral prophylactic mastectomy - a 30 year experience <i>Mr Narendra Nath Basu, University Hospital of South Manchester</i>
10:12 to 10:20	18. Predict: a population-based prognostic model for early breast cancer that includes Ki67 <i>Prof Gordon Wishart, Anglia Ruskin University, Cambridge</i>

11:00 to 12:30	Exchange Auditorium
Session 4	Breast Cancer Screening
Chair:	Mr Mark Sibbering
11:00 to 11:25	The independent review of breast cancer screening <i>Prof John Dewar, Ninewells Hospital, Dundee</i>
11:25 to 11:45	Breast Screening: how can we as surgeons improve the programme? <i>Prof Michael Dixon, Western General Hospital, Edinburgh</i>
11:45 to 11:55	Pathology and risks of B3 breast lesions <i>Dr Rahul Deb, Royal Derby Hospital</i>
11:55 to 12:05	UK management of B3 breast lesions <i>Dr Nisha Sharma, Leeds Teaching Hospitals</i>
12:05 to 12:25	Intact percutaneous excision of high risk breast lesions <i>Dr Pat Whitworth, Nashville Breast Center, USA</i>
	Discussion

Tuesday 21st May 2013

11:00 to 12:30 Exchange 8 - 10

Session 5 Mammary Fold Session

Chair: Miss Sue Down

11:00 to 11:30 **Multidisciplinary Breast Surgery Fellowships at the Mayo Clinic**
Dr Judy Boughey, Mayo Clinic, USA

11:30 to 12:00 **Dealing with the complications of Breast Reconstruction Surgery**
Mr Graeme Perks, Nottingham City Hospital

12:00 to 12:30 **Neoadjuvant treatment - surgical issues**
Miss Fiona MacNeill, Royal Marsden Hospital, London

11:00 to 12:30 Exchange 11

Session 6 Personal Finance Planning (Sponsored Session)

11:00 to 11:45 **Changes to pension legislation and NHS pension changes**
Mrs Kaye Price and Mr Rick Lee, Wesleyan Medical Sickness

11:45 to 12:30 **Inheritance tax planning**
Mrs Puja Crudden and Mr Ian Massey, Wesleyan Medical Sickness

Session sponsored by Wesleyan Medical Sickness

14:00 to 15:00 Exchange Auditorium

Session 7 The Axilla

Chair: Mr Dick Rainsbury

14:00 to 14:30 **BJS** **British Journal of Surgery Lecture:**
The timing of sentinel node biopsy in patients receiving neoadjuvant chemotherapy
Dr Judy Boughey, Mayo Clinic, USA

14:30 to 15:00 **Summary of 2012 ABS consensus and 2013 MDT questionnaire results**
Mr Kieran Horgan, Leeds Teaching Hospitals

Tuesday 21st May 2013

15:00 to 16:00	Exchange Auditorium
Session 8	Partial Breast Radiotherapy
Chair:	Prof Michael Kerin
15:00 to 15:15	Different techniques and the current evidence <i>Prof John Dewar, Ninewells Hospital, Dundee</i>
15:15 to 15:30	TARGIT trial results update <i>Mr Mo Keshtgar, Royal Free Hospital, London</i>
	TARGIT Trial results commentary: Is there sufficient evidence to make the technique widely available?
15:30 to 15:40	The Radiation Oncologist's View <i>Prof David Dodwell, Leeds Teaching Hospitals</i>
15:40 to 15:50	The Surgeon's view <i>Prof John Benson, Addenbrooke's Hospital, Cambridge</i>
	Discussion

15:00 to 16:00	Exchange 8 - 10
Session 9	The Breast Care Nurse's role in Breast Cancer Screening
Chair:	Mrs Sue Holcombe
15:00 to 15:30	Breast Screening - the controversy: How can Breast Care Nurses help support women in their decision making? <i>Mrs Margaret Casey, Royal Wolverhampton NHS Trust</i>
15:30 to 16:00	Telephoning benign results - one unit's experience <i>Mrs Claire Bailey, SW Thames Breast Screening</i>

15:00 to 16:00	Exchange 11
Session 10	Submitted Papers
Chairs:	Miss Julie Doughty & Mr Lee Martin
15:00 to 15:08	19. Sentinel lymph node mapping failure and axillary disease burden in invasive breast cancer - a cohort study <i>Mr David Bosanquet, Nevill Hall Hospital, Abergavenny</i>
15:08 to 15:16	20. Molecular analysis of whole sentinel lymph node (SLN) in breast cancer using OSNA (One Step Nucleic Acid) intraoperatively: prospective data over four years <i>Ms Mahwash Babar, Royal Surrey County Hospital, Guildford</i>
15:16 to 15:24	21. Is completion axillary lymph node dissection necessary in the presence of metastasis in the sentinel lymph node? <i>Prof Arnie Purushotham, King's College London</i>
15:24 to 15:32	22. Have we changed the management of axilla with positive sentinel node biopsy in breast cancer since the introduction of NICE guidelines in 2009? <i>Dr Emma Blower, Royal Liverpool & Broadgreen University Hospitals</i>
15:32 to 15:40	23. Axillary pathology complete response rates in node positive breast cancer patients after neo-adjuvant chemo or endocrine therapy <i>Mr Panagiottis Pappas, Royal Marsden NHS Foundation Trust, Sutton</i>
15:40 to 15:48	24. Relationship between aspirin use after diagnosis of breast cancer and survival in a cohort of Scottish women <i>Mr David Fraser, University of Dundee</i>
15:48 to 15:56	25. Experience of delivering intra-operative radiotherapy in a DGH <i>Mrs Archana Shetty, Royal Hampshire County Hospital, Winchester</i>

Tuesday 21st May 2013

16:30 to 18:00 Exchange Auditorium

Session 11 Familial Breast Cancer

Chair: Mrs Katy Hogben

16:30 to 16:45 **Bilateral risk reducing mastectomy – the evidence**
Dr Judy Boughey, Mayo Clinic, USA

16:45 to 17:00 **Bilateral risk reducing mastectomy – technical aspects**
Mr Douglas Macmillan, Nottingham City Hospital

17:00 to 17:15 **Bilateral risk reducing mastectomy – the Manchester experience**
Prof Andrew Baildam, St Bartholomew's Hospital, London

17:15 to 17:30 **Breast cancer management in women at high familial risk**
Mr Mark Sibbering, Royal Derby Hospital

17:30 to 17:40 Discussion

17:40 to 18:00 **The current evidence for breast cancer prevention in women at increased risk**
Prof Norman Wolmark, Allegheny General Hospital, Pittsburgh, USA

16:30 to 18:00 Exchange 8 - 10

Session 12 Breast Cancer Research & Trials

Chair: Mr Kieran Horgan

16:30 to 16:50 **Writing a successful grant application**
Prof Robert Mansel, University Hospital of Wales, Cardiff

16:50 to 17:10 **Setting up a clinical trial**
Prof Alastair Thompson, Ninewells Hospital, Dundee

17:10 to 17:30 **What's new in breast cancer research – highlights from 2012-2013**
Prof Michael Kerin, University College Hospital, Galway

17:30 to 17:40 **The Breast Cancer Campaign tissue bank**
Prof Valerie Speirs, University of Leeds

17:40 to 18:00 **Future surgical input into breast cancer research**
Prof John Robertson, Royal Derby Hospital

Discussion

16:30 to 18:00 Exchange 11

Session 13 Everyday surgical issues

Chair: Mr Simon Cawthorn

16:30 to 16:55 **Dealing with complaints**
Mr Martin Lee, Arden PCT Cluster

16:55 to 17:20 **Dealing with litigation**
Mr Tim Davidson, Royal Free Hospital, London

17:20 to 17:45 **Colleagues in difficulty/ difficult colleagues**
Mr Steve Holt, Chesterfield Royal Hospital

17:45 to 18:00 General Discussion

18:00 to 19:00 Poster Viewing and Drinks Reception (Exchange Hall)

Wednesday 22nd May 2013 – At a glance

	Exchange Auditorium	Exchange 8 - 10	Exchange 11
08:30 to 10:30	Session 14 Breast Cancer Audits	Session 15 Implant Based Breast Reconstruction	
10:30 to 11:00	Tea & Coffee Break (Exchange Hall)		
11:00 to 11:30	Session 16 Invited Lecture		
11:30 to 13:00	Session 17 Oncoplastic Breast Surgery	Session 18 Nursing submitted papers and debate	Session 19 Techniques and Technologies
13:00 to 14:00	Lunch (Exchange Hall)		
14:00 to 14:30	Session 20 EJSO Lecture		
14:30 to 16:30	Session 21 Systemic Adjuvant Treatment	Session 22 Poster Presentation Session	

Wednesday 22nd May 2013

08:30 to 10:30	Exchange Auditorium
Session 14	Breast Cancer Audits
Chair:	Mr Mark Sibbering
08:30 to 08:40	NHS Breast Screening Programme in the restructured NHS <i>Prof Julietta Patnick, Director, NHS Cancer Screening Programmes</i>
08:40 to 10:30	Breast Audit Data Presentation <i>Dr Gill Lawrence, West Midland Cancer Intelligence Unit</i> Commentators: <i>Pathology: Dr Rahul Deb, Royal Derby Hospital</i> <i>Surgery: Prof Michael Dixon, Western General Infirmary, Edinburgh</i> <i>Clinical Oncology: Prof David Dodwell, Leeds Teaching Hospitals</i> <i>Radiology: Dr Nisha Sharma, Leeds Teaching Hospitals</i>

Wednesday 22nd May 2013

08:30 to 10:30	Exchange 8 - 10
Session 15	Implant Based Breast Reconstruction
Chairs:	Mr Dick Rainsbury & Mr Graeme Perks
08:30 to 08:40	Implant based breast reconstruction – current indications and concerns <i>Mr Dick Rainsbury, Royal Hampshire County Hospital, Winchester</i>
08:40 to 08:50	Oncoplastic guidelines for acellular dermal matrices in breast reconstruction <i>Mr Lee Martin, Aintree University Hospital, Liverpool</i>
08:50 to 09:00	Experience and indications for breast reconstruction using acellular dermal matrices <i>Mr Richard Johnson, South Manchester University Hospital</i>
09:00 to 09:10	Prospective outcomes trial of immediate, implant breast reconstruction using acellular dermal matrix (POBRAD Trial) <i>Mr Michael Douek, Kings College London</i>
09:10 to 09:25	Experience and indications for myodermal flap based breast reconstruction <i>Ms Pilar Matey, New Cross Hospital, Wolverhampton</i>
09:25 to 09:40	Implant based breast reconstruction using a titanium-coated polypropylene mesh <i>Dr Stephan Paepke, Technical University of Munich, Germany</i>
09:40 to 09:55	Submuscular tissue expansion – still a good option <i>Mr Andrew Baidam, St Bartholomew's Hospital, London</i>
09:55 to 10:05	ABS/ BAPRAS audit of implant reconstruction using acellular dermal matrices and other new techniques <i>Mr Steven Thrush, Worcestershire Royal Hospital</i>
	Discussion

11:00 to 11:30	Exchange Auditorium
Session 16	Invited Lecture
Chair:	Miss Fiona MacNeill
11:00 to 11:30	Hormonal treatment of breast cancer: translating science into treatment <i>Prof Mitch Dowsett, Royal Marsden Hospital, London</i>

11:30 to 13:00	Exchange Auditorium
Session 17	Oncoplastic Breast Surgery
Chair:	Mr Lee Martin
11:30 to 11:45	Has the time come for a national protocol for managing surgical excision margins? <i>Prof Robert Mansel, University Hospital of Wales, Cardiff</i>
11:45 to 12:00	Preserving oncological principles in the oncoplastic era <i>Mr Douglas Macmillan, Nottingham City Hospital</i>
12:00 to 12:10	Discussion
12:10 to 12:30	Breast reconstruction in 2020 – where are we heading? <i>Mr Graeme Perks, Nottingham City Hospital</i>
12:30 to 13:00	Interactive oncoplastic case discussion <i>Mr Douglas Macmillan, Nottingham City Hospital</i> Panel: <i>Mr Lee Martin, Aintree University Hospital, Liverpool</i> <i>Prof Robert Mansel, University Hospital of Wales, Cardiff</i> <i>Mr Graeme Perks, Nottingham City Hospital</i> <i>Mr John Scott, Glasgow Royal Infirmary</i>

Wednesday 22nd May 2013

11:30 to 13:00	Exchange 8 - 10												
Session 18	Nursing Submitted Papers and Debate												
Chair:	Mrs Maria Noblet												
11:30 to 11:40	26. Ensuring nursing provision for people with metastatic breast cancer <i>Mrs Tara Beaumont, Breast Cancer Care</i>												
11:40 to 11:50	27. The patient experience of 'short stay/ 23 hour discharge' following mastectomy - a qualitative study <i>Mrs Julia Lambert, Royal Marsden Hospital, Sutton</i>												
11:50 to 12:00	28. An evaluation to assess the impact of a structured healthy living programme on women following breast cancer treatment <i>Mrs Karen Flores, James Paget University Trust Hospital</i>												
12:00 to 13:00	Debate: Fifty shades of pink: breast cancer awareness month does not benefit patients <table border="0"> <tr> <td>For:</td> <td>Proposer:</td> <td><i>Ms Lis Grimsey</i></td> </tr> <tr> <td></td> <td>Seconder:</td> <td><i>Mr Mark Kissin</i></td> </tr> <tr> <td>Against:</td> <td>Proposer:</td> <td><i>Dr Emma Pennery</i></td> </tr> <tr> <td></td> <td>Seconder:</td> <td><i>Mr Charlie Chan</i></td> </tr> </table>	For:	Proposer:	<i>Ms Lis Grimsey</i>		Seconder:	<i>Mr Mark Kissin</i>	Against:	Proposer:	<i>Dr Emma Pennery</i>		Seconder:	<i>Mr Charlie Chan</i>
For:	Proposer:	<i>Ms Lis Grimsey</i>											
	Seconder:	<i>Mr Mark Kissin</i>											
Against:	Proposer:	<i>Dr Emma Pennery</i>											
	Seconder:	<i>Mr Charlie Chan</i>											

11:30 to 13:00	Exchange 11
Session 19	Techniques and Technologies (Sponsored Session)
Chair:	Mr Simon Cawthorn
11:30 to 12:15	Kinesio Taping as a treatment of swelling and for scar reduction post surgery <i>Mrs Justine Whitaker, University of Central Lancashire</i>
12:15 to 12:35	Intra-operative imaging of sentinel lymph nodes <i>Dr James Recabaran, Huntingdon Hospital, Pasadena, USA</i> <i>Dr Dina Fouad & Mrs Teresa Fernandez, Edinburgh Breast Unit</i>
12:35 to 12:45	Discussion
12:45 to 12:55	Intra-operative imaging of therapeutic mammoplasty specimens <i>Dr Ewa Majdak-Paredes, Edinburgh Breast Unit</i>
12:55 to 13:00	Discussion
<i>Session sponsored by Kinesio UK and DAAX Ltd</i>	

14:00 to 14:30	Exchange Auditorium
Session 20	EJSO Lecture
Chair:	Mr Kieran Horgan
14:00 to 14:30	Extending adjuvant endocrine treatment <i>Prof John Forbes, Newcastle Mater Misericordiae Hospital, Australia</i>

Wednesday 22nd May 2013

14:30 to 16:30	Exchange Auditorium
Session 21	Systemic Adjuvant Treatment
Chair:	Miss Julie Doughty
14:30 to 14:50	Use of gene expression profiling <i>Prof Norman Wolmark, Allegheny General Hospital, Pittsburgh, USA</i>
14:50 to 15:10	IHC4 <i>Prof Mitch Dowsett, Royal Marsden Hospital, London</i>
15:10 to 15:30	Systemic adjuvant therapy decision making in 2013 – the Oncologist's view <i>Dr Mark Harries, Guy's & St Thomas' Hospital</i>
15:30 to 16:30	Panel discussion and interactive case discussion Panel: <i>Prof Mitch Dowsett</i> <i>Prof John Forbes</i> <i>Dr Mark Harries</i> <i>Prof Norman Wolmark</i>
14:30 to 15:30	Exchange 8-10
Session 22	Poster Presentation Session
Chairs:	Prof Alastair Thompson & Mrs Katy Hogben
	Oral presentation of the best 10 posters

KINESIO TAPING WORKSHOPS

Exchange 11 • 14:00 to 16:30

Kinesio UK will be running a series of 30 minute workshops on Wednesday 22nd May from 14:00 to 16:30.

To book a space to attend one of the workshops please visit the Kinesio UK stand in the exhibition.



Diary Date

ABS Conference & AGM
19th & 20th May 2014
ACC Liverpool

Invited Lecturers

Dr Judy Boughey

Judy Boughey MB, BChir, is Associate Professor of Surgery at Mayo Clinic Rochester. She received her first class degree in Physiology and medical degree from Cambridge University and completed her house officer year in the UK. She then moved to the United States, where she completed her general surgical residency at the University of South Carolina in Columbia, SC and breast surgical oncology fellowship at the University of Texas M.D. Anderson Cancer Center. She joined the Mayo Clinic as a consultant in 2006.

Her clinical practice focuses on the surgical management of breast cancer and she is actively involved with education of surgical residents as well as being Program Director of the Mayo Clinic Multidisciplinary Breast Surgery Fellowship. Her research interests involve clinical and translational research in breast cancer, with particular interest in molecular breast imaging, neoadjuvant chemotherapy for breast cancer, axillary ultrasound for preoperative staging, regional anesthesia for breast surgery and risk reducing mastectomy.



Dr. Boughey is the author of over 100 scientific papers and book chapters and has been an invited presenter at numerous national and international meetings, including the Society of Surgical Oncology, American Society of Breast Surgeons, American College of Surgeons, the Brazilian Congress of Mastology and the Sao Paulo Breast Cancer Conference. She is actively involved with clinical trial development nationally and sits on the Breast Oncology Local Disease Taskforce (an advisory taskforce to the NIH).

She is the national PI of several clinical trials, including the ACOSOG Z1071 study which evaluated the role of sentinel lymph node surgery after neoadjuvant chemotherapy in women with node positive breast cancer, and is PI of the successor trial looking to minimize axillary surgery for node positive breast cancer patients treated with neoadjuvant chemotherapy (A11202). She is also PI of Z11102 evaluating breast conservation for women with multiple ipsilateral breast cancers. She is the Vice-Chair of the Education Committee of the American College of Surgeons Clinical Research Program (ACS-CRP).

Professor Mitch Dowsett

Professor Mitch Dowsett, PhD, is Head of the Academic Department of Biochemistry at the Royal Marsden Hospital, Professor of Biochemical Endocrinology at the Institute of Cancer Research, and Professor of Translational Research in the Breakthrough Breast Cancer Centre, London. He has recently become Head of the Centre for Molecular Pathology based at the Royal Marsden Hospital, Sutton.

His research focuses almost exclusively on breast cancer and predominantly on hormonal aspects of the disease and biomarkers of response. He has been closely involved with the clinical development of aromatase inhibitors and the establishment of Ki67 as an intermediate marker of treatment benefit.

He has authored over 500 published papers related to breast cancer, and was the 2007 William L McGuire Memorial Lecturer.

He is a board member of the Breast International Group (BIG), and sits on the Executive/Steering Committees of several clinical trials. He is the founding chairman of the NCRI Translational Clinical Study Group and is a member of the NCRI Breast Cancer Study Group.

He was an author of both the UK and the ASCO/CAP guidelines for HER2 diagnostics. He is the international member of the ASCO/CAP Steering Committee for ER/PgR IHC guidelines.



Invited Lecturers continued...



Professor John Forbes

Professor John Forbes, AM, MS, FRACS, FRCS, has been involved in breast cancer research throughout his professional career, in particular, with national and international clinical trials to develop new treatments for all types of breast cancer and ultimately for prevention of breast cancer.

He is Professor of Surgical Oncology at the University of Newcastle (Australia); Director, Department of Surgical Oncology at the Calvary Mater Newcastle Hospital; and Director of Research for the Australia and New Zealand Breast Cancer Trials Group.

He completed his medical studies and surgical training at the University of Melbourne and the Royal Melbourne Hospital, and was awarded the Australian Nuffield Fellowship in Medicine and studied at the Welsh National Medical School, Cardiff, Wales.

On his return to Australia, he was instrumental, together with other clinicians, in establishing the ANZ Breast Cancer Trials Group, and the International Breast Cancer Study Group, formerly known as the Ludwig Breast Cancer Study Group.

Professor Forbes has been invited visiting Professor in many countries, has presented papers at scientific meetings throughout the world, and published over 400 papers on many aspects of breast cancer – in particular on prevention and endocrine treatment of breast cancer. He chairs and co-chairs, or is a member of Steering Committees for national and international breast cancer clinical trials, including ATAC, ATLAS, IBIS I and II, BIG 1-98, and IES.

In 2007 he was recognised as one of the top 10 most highly cited researchers in the world for peer-reviewed publications in 2005-2006. In November 2010 he was awarded the Clinical Oncological Society of Australia's (COSA) Tom Reeve Oration Award for Outstanding Contributions to Cancer Care and in 2012 he was awarded a Member of the Order of Australia (AM), being recognised for service to medicine in the field of breast cancer research, to the development of improved clinical practice standards and service to the community.

Professor Norman Wolmark

Norman Wolmark, M.D. is Chairman and Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP) which is funded by the NCI and is based on the campus of Allegheny General Hospital in Pittsburgh, Pennsylvania. He is also Professor of Surgery at the Temple University School of Medicine and is a breast surgeon at Allegheny General Hospital, Pittsburgh, Pennsylvania.

Professor Wolmark gained his MD at McGill University, Montreal, Canada and he subsequently completed his residency at the University of Pittsburgh. Professor Wolmark was then appointed to the position of Cancer Expert at the Surgery Branch of the National Cancer Institute, Bethesda, Maryland. Professor Wolmark is a member of numerous professional societies, including the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the American Surgical Association (ASA).



He is a reviewer for the Journal of Clinical Oncology and the New England Journal of Medicine, and he also serves on numerous boards and as an advisor to oncology programs, societies and institutes throughout the United States, Europe and Asia.

List of Exhibitors

Trade Exhibition

The Exhibition will be held in the Exchange Hall and will be open at the following times:

Tuesday 21st May 2013: 07:45 to 19:00

Wednesday 22nd May 2013: 08:00 to 14:00

The exhibition will contain the following stands:

Allergan

Allergan is a multi-specialty health care company established more than 60 years ago dedicated to uncovering the best of science and developing meaningful treatments to help people reach their life's potential. Today, we have more than 9,000 talented employees with a presence in more than 100 countries. Our portfolio includes pharmaceuticals, biologics and medical devices. From our beginnings as an eye care company to our focus today on several medical specialties, including ophthalmology, neurosciences, medical aesthetics, breast aesthetics and obesity intervention. Allergan is proud to celebrate more than 60 years of medical advances and are proud to help millions of patients see more clearly, move more freely and express themselves more fully.

Avail Medical

Electrosurgery, Gamma Probes and Headlights

Bard Limited

For more than 100 years, C. R. Bard, Inc. has been developing innovative medical devices that meet the needs of healthcare professionals and patients. From a one man shop in 1907 to a global leader in the medical device industry we are committed to enhancing the lives of people around the world. Our five divisions focus their efforts around the disease areas of: Vascular, Urology, Oncology and Surgical Specialties.

Our 12,000 employees are committed to creating innovative, potentially life-saving medical technology products that improve the quality of life for patients worldwide.

Blackwell's Exhibitions

Blackwell's have been supplying specialist publications and academic books for over 130 years and are a contracted supplier to the NHS and Department of Health. Blackwell Exhibitions specialises in bringing event specific books to UK Medical meetings, offering delegates a range of titles seldom found together elsewhere.

BCCOM/ Sloane Project

The Breast Cancer Clinical Outcome Measures (BCCOM) Project is the online audit of symptomatic breast cancers. The Sloane Project is a UK prospective audit of screen-detected non-invasive carcinomas and atypical hyperplasias of the breast.

Breakthrough Breast Cancer

Breakthrough Breast Cancer is committed to campaigning to change lives and shape futures by securing improvements in breast cancer prevention, diagnosis, treatment and services for everyone affected by breast cancer. We are determined to create a future free from the fear of breast cancer.

Breast Cancer Care

Breast Cancer Care is here for anyone affected by breast cancer. We bring people together, provide information and support, and campaign for improved standards of care. We use our understanding of people's experience of breast cancer and our clinical expertise in everything we do. Find out more at www.breastcancercare.org.uk

Bright Technologies Ltd

Specialists in all types of intra-operative radiation detection and mapping. Our range includes the EUROPROBE systems for Sentinel Lymph Node Biopsy, Lymph Node Mapping, Tumour Marking, etc. Our range has the ability to detect many types of radioactive particles ranging from 20KeV - 1000KeV.

CareFusion

CareFusion is a global corporation serving the healthcare industry with products and services that help hospitals measurably improve patient care. Focused on reducing medication errors and hospital-acquired infections, CareFusion's family of products includes ChlorPrep® patient preoperative skin preparation.

ChlorPrep reduces microorganisms on patients' skin prior to medical and surgical procedures. This one-step antiseptic system lowers the risk of dangerous bloodstream and surgical site infections. The efficacy and safety of ChlorPrep are supported by more than 35 clinical studies and recommendations by 17 internationally recognized organisations or guidelines, including 10 that specifically recommend 2% chlorhexidine gluconate - a key ingredient in ChlorPrep

List of Exhibitors continued...

DAAX Ltd

DAAX supply the Faxitron VISION range of Digital Specimen Systems for use in theatre, radiology and pathology. Faxitron BioVision is portable and can be safely and easily moved between different theatre locations. The Surgeon can within 10 seconds have an image of the excised tissue enabling a decision to be made to 'close' or take further margin. The high sensitivity of the detector will clearly identify the presence of very fine calcification within lumpectomy. This can be enhanced significantly further by using the magnification levels to acquire even higher resolution images. Typically BioVision saves 20 minutes per procedure.

Devicor Medical UK Ltd

The neo2000® Gamma Detection System (GDS) is the centrepiece of gamma-guided surgical procedures such as lymphatic mapping and parathyroidectomy, and it may help spare patients from complications associated with complete lymph node dissection.

The Mammotome® revole™ is the only device to offer advanced tissue management technology. It is designed to empower clinical decision making, increase procedural efficiency and provide optimized sample reliability. Mammotome® revole™ puts information ease and clinical reassurance at your fingertips.



Quality is a necessity, not a luxury.

MENTOR® & PERTHESE™ Breast Implants

50 years of combined breast
aesthetics excellence.¹

As the world leading manufacturer of high-quality breast implants, our experience results in products that you can rely on and that are made under strict standards of design and testing.

Our breast implants comply with applicable standards and regulations:

- CE mark approval under the Medical Device Directive 93/42/EEC²
- US FDA approval³
- ISO 10993:1⁴
- ISO 14607⁵
- ISO 13485⁶



 **MENTOR**
Make life more beautiful™

1 Data on File at Mentor Worldwide LLC / 2 Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, updated 2007 / 3 FDA Approval for MENTOR® MemoryGel™ Round Profile Cohesive I™ Breast Implants and MENTOR® Saline-Filled Breast Implants / 4 ISO 10993:1 "Biological Evaluation of Medical Devices" - International Organization for Standardization, Geneva, Switzerland. / 5 Ibid - ISO 14607 "Non-active surgical implants - Mammory Implants - Particular requirements" / 6 Ibid - "Medical devices - Quality management systems - Requirements for regulatory purposes"

List of Exhibitors continued...

Elswood

Elswood Medical Innovation introduces the BLES (Breast Lesion Excision System) as produced by Intact Medical Corp. of the USA. This sophisticated new system for surgeons, oncologists and radiologists allows macro-biopsies to be created which are completely intact including a margin around the lesion, giving the pathologist a sample which will allow a much clearer picture of the lesion and its structure and hence a better diagnosis. Elswood also offers and markets the SAVI® breast brachytherapy applicator. The SAVI technology allows physicians to precisely target radiation to the area that needs it most, minimising exposure to healthy tissue.

Eurosurgical Ltd

Eurosurgical Ltd are looking forward to welcoming all surgeons to our stand. We shall be featuring a wide range of products and services that encompass all areas of reconstructive breast surgery. The FDA approved Silimed range of breast implants include the Pure - Polyurethane BioDesign range. Over 120 published clinical articles show that these implants have the lowest reported complication rates for any breast implant and particularly low incidents of Capsular Contracture. Available in 5 styles, including two round base and three anatomical. Insorb, a subcuticular, absorbable staple, that fires the small 3/0 staples horizontally into the dermis, but not through the skin, for fast and effective wound closure. Fat harvesting equipment and cannula, Snowden Pencer range of breast instruments and the Design Veronique post-operative support garments.

Genomic Health Inc

Genomic Health Inc. located in Redwood City, California was founded in 2000 and has currently over 500 employees worldwide. The company develops and commercialises genomic-based clinical laboratory services for diagnostics. These analyse the underlying biology of cancer allowing doctors and patients to make individualised treatment decisions.

Hologic UK Ltd

Hologic Inc is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems and surgical products dedicated to serving the healthcare needs of women, with a focus on mammography, breast biopsy and radiation treatment for early-stage breast cancer.

IGEA UK

IGEA Medical has been committed to research and innovation in medical devices for over 30 years. Over the last ten years we have developed an innovative approach to treating cutaneous and sub-cutaneous tumours via 'electrochemotherapy' using the IGEA Cliniporator device. The Electrochemotherapy technique combines electroporation (formation of temporary pores in the tumour cell membrane via an electrical pulse delivered by the IGEA Cliniporator); with a low level dose of chemotherapy. It is a clinical proven way of treating patients with local chest wall recurrence or skin metastases from breast cancer (including difficult fungated tumours), irrespective of current or prior treatments.

Kinesio UK

Kinesio UK offers the only Kinesio Taping training courses in the UK endorsed by the Kinesio Taping Association International founded by Dr Kase and leading to certification recognised worldwide. Kinesio is an effective therapeutic and rehabilitative taping innovation cutting sport injury recovery times and aiding lymphoedema reduction. Used by elite athletes, Kinesio is fundamentally different to traditional strapping techniques. Using a unique adhesive tape, Kinesio Tex, alongside specialist applications, Kinesio provides muscle support during activity, without affecting range of motion and facilitates lymphatic flow.

LifeCell

Since 1994 LifeCell Corporation has been a pioneer in the science of regenerative medicine. LifeCell Corporation Tissue Matrices have been used successfully in more than one million grafts and implants to date. The range of surgical applications include hernia repair, breast reconstruction post-mastectomy, breast plastic surgery (breast augmentation revisions) and other reconstructive applications. Since 2008 our next generation soft-tissue repair product, Strattice™ Reconstructive Tissue Matrix, is being used by an increasing number of surgeons worldwide for hernia and abdominal wall repair and breast reconstruction.

Mammary Fold

Breast trainees group.

Mentor Medical Systems

At Mentor it is our aim to be the trusted leader in aesthetics among consumers & professionals to maintain, enhance and restore self esteem & quality of life. Mentor manufacture a complete range of breast prosthesis and tissue expanders and is a member of the Johnson & Johnson family of medical companies.

List of Exhibitors continued...

Nagor Ltd

Nagor is the only British company dedicated to the specialist design, manufacture and supply of high quality breast implants and related medical devices. Our portfolio includes anatomical and round silicone implants, external port and integrated valve tissue expanders, sizers as well as other types of body aesthetic implants.

Nicola Jane

Experts in post-surgery fashion for over 29 years, helping to restore confidence and femininity after breast cancer.

Novartis Oncology

Our mission at Novartis is to discover, develop and successfully market innovative products to prevent diseases, to ease suffering and to enhance quality of life. As one of the largest pharmaceutical businesses in the world, Novartis has a responsibility to protect and invest for the future. In 2009 Novartis invested US \$7.5 bn in research and development. Novartis Oncology has a strong heritage in cancer care. Indeed, over the last 25 years pioneering research has repeatedly resulted in new and innovative products, like the cutting edge, rationally designed, molecularly targeted compounds. See www.novartis.co.uk

Oncotherapy Resources Ltd

Oncotherapy Resources Ltd (ORL) is a brand new company offering a new, electronic brachytherapy device that can deliver single fraction breast radiotherapy, intra-operatively at the time of lumpectomy (IORT) and can now be delivered to any hospital location to more easily meet the needs of selected patients. The Xoft Axxent eBx system is now available as a fully mobile, managed and delivered service on a cost per patient treated basis enabling the NHS or private sector to more easily adopt the technique now and without the need for a capital equipment purchase.

Operating Room Systems Ltd

Operating Room Systems supply a range of general surgical and minimally invasive devices across the clinical spectrum. Our portfolio includes the Gamma Finder device for sentinel node localisation. Our corporate ethos is to drive innovation into the market supported with robust service provision and technical backup.

view more see more

Taking a closer look at intraoperative imaging of lymph nodes and breast specimens.

Wed 22 May Techniques & Technologies - Session 19 - Exchange 11

12.15 - 12.35	Intraoperative imaging of sentinel lymph nodes Dr James Recabaran, Huntingdon Hospital, Pasadena, USA and Dr Dina Fouad & Teresa Fernandez, Edinburgh Breast Unit
12.35 - 12.45	Discussion
12.45 - 12.55	Intraoperative imaging of therapeutic mammoplasty specimens Dr Ewa Majdak-Paredes, Edinburgh Breast Unit
12.55 - 13.00	Discussion

Visit us at Stand 10

ABS Conference & AGM
21 - 22 May 2013
Manchester Central

Exclusive Faxitron distributor
for the UK and Ireland
www.daax.co.uk

daax

List of Exhibitors continued...

pfm Medical UK Ltd

TiLOOP® Bra is the unique extralight and ultrasoft, titanized meshes for onco-plastic breast reconstruction. Due to its high biocompatibility, TiLOOP® Bra offers excellent surgical results whilst conserving a natural feeling for the patient and restoring quality of life.

For over 40 years, products and systems from pfm medical have been firmly established in hospital, laboratory, and nursing environments. As a partner for medical technology over this long period, we have made a major contribution to enhancing the safety and efficiency of medical care, thanks to our innovative strength, high investment in research, in-depth market experience and constantly reliable quality.

Q Medical Technologies

Q Medical supply and support the Polytech range of German Breast implants along with Surgimend, a Bovine based ADM for breast and abdominal wall reconstruction.

Roche

Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Roche in the UK employs nearly 2,000 people in pharmaceuticals and diagnostics. For more information: www.roche.co.uk

Surgical Indemnity Scheme

The Surgical Indemnity Scheme (SIS) is exclusively for UK surgeons and is wholly owned by ASGBI. SIS provides a comprehensive indemnity including: independent sector clinical negligence claims; GMC investigations; NHS complaints and capability procedures; inquests; police investigations; and other legal problems arising from surgical practice. All SIS services are accessed through the 24 hour medico-legal advisory service. SIS indemnity meets all independent hospitals requirements and provides protection into retirement with 10 years free run-off cover. SIS provides the security, expertise and value you need to practise with complete peace of mind.

Sysmex UK Limited

With over 40 years' experience, as a leading company in the field of in-vitro diagnostics Sysmex continues to develop and market advanced technologies. In the Life Science field we strive to improve cancer treatment. OSNA provides optimised nodal staging of patients in an intra-operative setting with more than 30,000 patients benefitting from this approach. The importance of accurate staging is recognised with the increasing trend to utilise the OSNA copy number as a predictive tool for appropriate axillary clearance. Now Sysmex are proud to market the SentiMag System for accurate identification of SLN during surgery without the requirement for radioisotope. Visit us at Exhibition Stand 31. www.sysmex-lifescience.com

Teasdale Surgical Ltd

Specialist in all forms of surgical retraction.

Thamert (UK) Ltd

Our 2013 range of Silima® breastforms, making use of state-of-the-art soft silicone technology, a good choice of fibrefill forms offering value for money, stylish and supportive bras.

Wellspect HealthCare

Wellspect HealthCare manufactures and distributes Wound Drainage and Wound Management devices for the care of Breast Surgery patients.

Wesleyan Medical Sickness

Wesleyan Medical Sickness is a specialist financial company. We have financial consultants that are specifically trained to understand the financial needs of hospital doctors throughout their career. We are regulated by the FSA (Financial Services Authority) and we have an advisory board made up of some of the most prominent members of the medical profession.

Womanzone Distribution Ltd

NHS-approved specialists in caring for women after breast surgery. Working with healthcare professionals and Breast Cancer Care in the education of bra and prostheses fitting. We offer a wide range of lingerie, made-to-measure swimwear, pocketing service and free fitting service. See www.woman-zone.co.uk

General information

Registration Desk

Registration will be open in the Exchange Foyer at the following times:

Tuesday 21st May 2013: 07:45 to 19:00

Wednesday 22nd May 2013: 08:00 to 16:30

Lunch and Refreshments

Lunch and refreshments will be served at the times listed in the programme in the Exchange Hall.

A/V Preview Room

An A/V Preview Room is available in Exchange Room 1 for the duration of the meeting.

Would any speaker who needs to hand their presentation in please take it to the room on arrival.

Posters

The poster presentations will be displayed in the Exchange Hall for the duration of the meeting. Please can all poster presenters mark and store their poster tubes in the boxes provided in the room. These will then be stored at registration. Posters should be removed between 13:45 and 14:00 on Wednesday 22nd May and can be stored at registration for the afternoon session if required. Posters left on the boards after this time will be removed and the ABS cannot be responsible for their safe return.

Cloakroom

A cloakroom and luggage store will be available in the Exchange Foyer for the duration of the meeting.

Security

In the interests of security, delegates are required to wear their name badges at all times during the meeting.

Prayer Room

A prayer room is available for the use of delegates. Please ask at Registration for further details.

CPD

The two day meeting has been awarded 13 CPD points by the Association of Surgeons of Great Britain and Ireland.

Photography

A photographer will be taking images of the conference on Tuesday 21st May for use in future ABS publications and on the ABS website. If you do not wish to have images of yourself used by the ABS please let Lucy Davies know by e-mail at: lucydavies@absghi.org.uk

ABS Annual Dinner

The Association of Breast Surgery Annual Dinner will be held at the Midland Hotel (Peter Street, Manchester, M60 2DS) on Tuesday 21st May 2013 at 7.30pm for 8pm. Dress is lounge suits.

This meeting is supported by educational grants from the Association of Breast Surgery's sponsors:



1st ABS Multidisciplinary Meeting

Neoadjuvant Treatment

20th January 2014

Royal College of Surgeons of England



The ABS will be holding a one day meeting on the topic of neoadjuvant treatment in London next January. The programme will be plenary sessions only and will be designed to enable discussion among members of the multidisciplinary team on the hot topic of neoadjuvant chemotherapy.

Further details will be available from the ABS in due course.



ABS Trainees Meeting

20th and 21st June 2013

Glasgow Royal Infirmary

For further details see:

www.associationofbreastsurgery.org.uk

or contact Krysia Cruickshank at:

Krysia.cruickshank@ggc.scot.nhs.uk

ABS
ASSOCIATION OF
BREAST SURGERY

Association of Breast Surgery
at The Royal College of Surgeons
35 – 43 Lincoln's Inn Fields
London WC2A 3PE

T 020 7869 6853

F 020 7869 6851

E office@absgbi.org.uk

W www.associationofbreastsurgery.org.uk